U is a selective estrogen receptor degrader (Selective estrogen receptor degraders (SERDs)) that is being evaluated as a once-daily oral treatment for patients with estrogen receptor-positive (ER+ ...

This is a new kind of oral selective estrogen receptor degrader (SERD), used to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast ...

The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...

The Fatima bint Mubarak Center at Cleveland Clinic Abu Dhabi, part of the M42 group, becomes the first center in the GCC ...

The EMBER-3 study introduced imlunestrant, an oral selective estrogen receptor degrader (SERD), as a potential treatment for hormone receptor–positive, HER2-negative metastatic breast cancer ...

DelveInsight’s, “Metastatic Breast Cancer Pipeline Insight” report provides comprehensive insights about 100+ companies and ...

Paolo Tarantino, MD, PhD, discusses the approval of the oral therapy elacestrant for patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations.

In a report released on January 29, Andrew Berens from Leerink Partners maintained a Hold rating on Zentalis Pharmaceuticals (ZNTL – Research ...

Morgan Stanley analyst Michael Ulz has maintained their neutral stance on ZNTL stock, giving a Hold rating yesterday.Invest with Confidence: ...

Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies ...